SEC Comment Letter 0000000000-24-011274 to Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc.
Date: Oct. 7, 2024 · CIK: 0001855485 · Accession: 0000000000-24-011274
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282456
Letter
October 7, 2024 Andrew Jackson Chief Financial Officer Calidi Biotherapeutics, Inc. 4475 Executive Dr., Suite 200 San Diego, CA 92121 Re:Calidi Biotherapeutics, Inc. Registration Statement on Form S-3 Filed October 1, 2024 File No. 333-282456 Dear Andrew Jackson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jay K. Yamamoto, Esq.
Show Raw Text
October 7, 2024
Andrew Jackson
Chief Financial Officer
Calidi Biotherapeutics, Inc.
4475 Executive Dr., Suite 200
San Diego, CA 92121
Re:Calidi Biotherapeutics, Inc.
Registration Statement on Form S-3
Filed October 1, 2024
File No. 333-282456
Dear Andrew Jackson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jay K. Yamamoto, Esq.